Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) Price Target at $21.75

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $21.75.

Several equities research analysts have recently weighed in on CLBT shares. Wall Street Zen raised Cellebrite DI from a “hold” rating to a “buy” rating in a research report on Friday, September 26th. Needham & Company LLC reduced their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Lake Street Capital reduced their target price on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 15th. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CLBT. Signaturefd LLC lifted its position in Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after purchasing an additional 819 shares during the period. Assetmark Inc. acquired a new position in Cellebrite DI during the first quarter worth $33,000. PNC Financial Services Group Inc. raised its stake in Cellebrite DI by 1,998.0% during the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after acquiring an additional 1,998 shares in the last quarter. Toth Financial Advisory Corp acquired a new position in Cellebrite DI during the third quarter worth $38,000. Finally, Catalyst Capital Advisors LLC acquired a new position in Cellebrite DI during the first quarter worth $51,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Up 0.3%

CLBT opened at $19.10 on Thursday. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30. The stock has a market capitalization of $4.57 billion, a price-to-earnings ratio of -25.13, a P/E/G ratio of 3.47 and a beta of 1.29. The business has a 50 day moving average of $16.71 and a 200-day moving average of $16.94.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million during the quarter, compared to analysts’ expectations of $112.33 million. During the same period in the prior year, the business earned $0.10 earnings per share. Cellebrite DI’s revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts predict that Cellebrite DI will post 0.3 EPS for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.